Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Study of SGN-35 in Patients With Relapsed/Refractory CD30-Positive Hematologic Malignancies.

NCT00430846 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT00430846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00430846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Study of SGN-35 in Patients With Relapsed/Refractory CD30-Positive Hematologic Malignancies.
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2006
Completion date
July 31, 2009
Enrollment
45 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

disease, hodgkin, lymphoma, large-cell, anaplastic, lymphoma, non-hodgkin